Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05320146 · ClinicalTrials.gov registry record
A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
A clinical trial, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- 22
- Enrollment target
NCT05320146: Completed study, sponsored by Corcept Therapeutics.
NCT05320146 is a clinical trial that has completed, run by Corcept Therapeutics. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05320146 has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
This optional sub study is a part of the phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
Interventions
- OTHER MRI-PDFF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2023-07-18 |
What the finished NCT05320146 record still lists
NCT05320146 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MRI-PDFF is the first listed.
NCT05320146 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05320146 about?
NCT05320146 is a clinical study titled "A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)". This optional sub study is a part of the phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
What is the current status of trial NCT05320146?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2022-03-04. Estimated completion is 2023-07-18.
What interventions are being tested in trial NCT05320146?
The interventions under investigation include: MRI-PDFF (OTHER).
Who is sponsoring clinical trial NCT05320146?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI